Socs7, a target gene of microRNA-145, regulates interferon-β induction through STAT3 nuclear translocation in bladder cancer cells

Cell Death and Disease

Volumn 4, Issue 2, 2013, Pages

  Noguchi, S ^a   Yamada, N ^a   Kumazaki, M ^a   Yasui, Y ^a   Iwasaki, J ^a   Naito, S ^b   Akao, Y ^a  

^a GIFU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Bladder cancer; Interferon ; MicroRNA 145; SOCS7; STAT3

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; BETA INTERFERON; CASPASE; CASPASE INHIBITOR; LUCIFERASE; MICRORNA 145; POLYINOSINIC POLYCYTIDYLIC ACID; PROTEIN KINASE B; RIBONUCLEASE L; STAT3 PROTEIN; TOLL LIKE RECEPTOR 3; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER CELL; CANCER GROWTH; CARCINOGENESIS; CONTROLLED STUDY; GENE EXPRESSION; GENE TARGETING; GENE TRANSLOCATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; RECEPTOR UPREGULATION; STATISTICAL SIGNIFICANCE; SUPPRESSOR OF CYTOKINE SIGNALING 7 GENE;

2',5'-OLIGOADENYLATE SYNTHETASE; APOPTOSIS; CASPASES; CELL LINE; CELL NUCLEUS; HUMANS; INTERFERON-BETA; MICRORNAS; NUCLEAR PROTEINS; POLY I-C; PROTO-ONCOGENE PROTEINS C-AKT; RNA INTERFERENCE; RNA, SMALL INTERFERING; STAT3 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TOLL-LIKE RECEPTOR 3; UP-REGULATION; URINARY BLADDER NEOPLASMS;

EID: 84875999010     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.11     Document Type: Article

References (32)

1. Ozen M, Creighton CJ, Ozdemir M, Ittmann M. Widespread deregulation of microRNA expression in human prostate cancer. Oncogene 2008; 27: 1788-1793.
2. Ichimi T, Enokida H, Okuno Y, Kunimoto R, Chiyomaru T, Kawamoto K et al. Identification of novel microRNA targets based on microRNA signatures in bladder cancer. Int J Cancer 2009; 125: 345-352.
3. Akao Y, Nakagawa Y, Naoe T. MicroRNA-143 and -145 in colon cancer. DNA Cell Biol 2007; 26: 311-320.
4. Akao Y, Nakagawa Y, Kitade Y, Kinoshita T, Naoe T. Downregulation of microRNAs-143 and -145 in B-cell malignancies. Cancer Sci 2007; 98: 1914-1920.
5. Noguchi S, Mori T, Hoshino Y, Maruo K, Yamada N, Kitade Y et al. MicroRNA-143 functions as a tumor suppressor in human bladder cancer T24 cells. Cancer Lett 2011; 307: 211-220.
6. Noguchi S, Mori T, Hoshino Y, Yamada N, Nakagawa T, Sasaki N et al. Comparative study of anti-oncogenic microRNA-145 in canine and human malignant melanoma. J Vet Med Sci 2012; 74: 1-8.
7. Noguchi S, Yasui Y, Iwasaki J, Kumazaki M, Yamada N, Naito S et al. Replacement treatment with microRNA-143 and -145 induces synergistic inhibition of the growth of human bladder cancer cells by regulating PI3K/Akt and MAPK signaling pathways. Cancer Lett 2013; 328: 353-361.
8. Sachdeva M, Zhu S, Wu F, Wu H, Walia V, Kumar S et al. p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc Natl Acad Sci USA 2009; 106: 3207-3212.
9. Chiyomaru T, Enokida H, Tatarano S, Kawahara K, Uchida Y, Nishiyama K et al. miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer. Br J Cancer 2010; 102: 883-891.
10. Gregersen LH, Jacobsen AB, Frankel LB, Wen J, Krogh A, Lund AH. MicroRNA-145 targets YES and STAT1 in colon cancer cells. PLoS One 2010; 5: e8836.
11. Xu N, Papagiannakopoulos T, Pan G, Thomson JA, Kosik KS. MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells. Cell 2009; 137: 647-658.
12. Ostenfeld MS, Bramsen JB, Lamy P, Villadsen SB, Fristrup N, Sorensen KD et al. miR-145 induces caspase-dependent and -independent cell death in urothelial cancer cell lines with targeting of an expression signature present in Ta bladder tumors. Oncogene 2010; 29: 1073-1084.
13. Sudbery I, Enright AJ, Fraser AG, Dunham I. Systematic analysis of off-target effects in an RNAi screen reveals microRNAs affecting sensitivity to TRAIL-induced apoptosis. BMC Genomics 2010; 11: 175.
14. Zaman MS, Chen Y, Deng G, Shahryari V, Suh SO, Saini S et al. The functional significance of microRNA-145 in prostate cancer. Br J Cancer 2010; 103: 256-264.
15. Ludwig AT, Moore JM, Luo Y, Chen X, Saltsgaver NA, O'Donnell MA et al. Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for Bacillus Calmette-Guerininduced antitumor activity. Cancer Res 2004; 64: 3386-3390.
16. Chawla-Sarkar M, Leaman DW, Borden EC. Preferential induction of apoptosis by interferon (IFN)-beta compared with IFN-alpha2: correlation with TRAIL/Apo2L induction in melanoma cell lines. Clin Cancer Res 2001; 7: 1821-1831.
17. Doly J, Civas A, Navarro S, Uze G. Type I interferons: expression and signalization. Cell Mol Life Sci 1998; 54: 1109-1121.
18. Svoboda P. Off-targeting and other non-specific effects of RNAi experiments in mammalian cells. Curr Opin Mol Ther 2007; 9: 248-257.
19. Borden EC, Sen GC, Uze G, Silverman RH, Ransohoff RM, Foster GR et al. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov 2007; 6: 975-990.
20. Li G, Xiang Y, Sabapathy K, Silverman RH. An apoptotic signaling pathway in the interferon antiviral response mediated by RNase L and c-Jun NH2-terminal kinase. J Biol Chem 2004; 279: 1123-1131.
21. de Veer MJ, Holko M, Frevel M, Walker E, Der S, Paranjape JM et al. Functional classification of interferon-stimulated genes identified using microarrays. J Leukoc Biol 2001; 69: 912-920.
22. Dong B, Silverman RH. 2-5A-dependent RNase molecules dimerize during activation by 2-5A. J Biol Chem 1995; 270: 4133-4137.
23. Castelli JC, Hassel BA, Wood KA, Li XL, Amemiya K, Dalakas MC et al. A study of the interferon antiviral mechanism: apoptosis activation by the 2-5A system. J Exp Med 1997; 186: 967-972.
24. Krebs DL, Hilton DJ. SOCS proteins: negative regulators of cytokine signaling. Stem Cells 2001; 19: 378-387.
25. Martens N, Uzan G, Wery M, Hooqhe R, Hooqhe-Peters EL, Gertler A. Suppressor of cytokine signaling 7 inhibits prolactin, growth hormone, and leptin signaling by interacting with STAT5 or STAT3 and attenuating their nuclear translocation. J Biol Chem 2005; 280: 13817-13823.
26. Yang J, Chatterjee-Kishore M, Staugaitis SM, Nguyen H, Schlessinger K, Levy DE et al. Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. Cancer Res 2005; 65: 939-947.
27. Nepple KG, Aubert HA, Braasch MR, O'Donnell MA. Combination of BCG and interferon intravesical immunotherapy: an update. World J Urol 2009; 27: 343-346.
28. Yoneyama M, Kikuchi M, Natsukawa T, Shinobu N, Imaizumi T, Miyagishi M et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 2004; 5: 730-737.
29. Kato H, Takeuchi O, Sato S, Yoneyama M, Yamamoto M, Matsui K et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 2006; 441: 101- 105.
30. Gitlin L, Barchet W, Gilfillan S, Cella M, Beutler B, Flavell RA et al. Essential role of mda-5 in type I IFN responses to polyriboinosinic: polyribocytidylic acid and encephalomyocarditis picornavirus. Proc Natl Acad Sci USA 2006; 103: 8459-8464.
31. Reich NC, Liu L. Tracking STAT nuclear traffic. Nat Rev Immunol 2006; 6: 602-612.
32. Naito S, Kotoh S, Koga H, Hasegawa S, Yamasaki T, Noma H et al. Establishment and characterization of two human bladder cancer cell lines. Hum Cell 1996; 9: 49-56.